NBTXR3

Phase 1/2Recruiting

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Locally-Advanced Non-Small Cell Lung Cancer

Conditions

Locally-Advanced Non-Small Cell Lung Cancer

Trial Timeline

Apr 30, 2026 → Aug 30, 2030

NCT ID

NCT07224152

About NBTXR3

NBTXR3 is a phase 1/2 stage product being developed by Nanobiotix for Locally-Advanced Non-Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07224152. Target conditions include Locally-Advanced Non-Small Cell Lung Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07224152	Phase 1/2	Recruiting	Apr 30, 2026	Aug 30, 2030	Locally-Advanced Non-Small Cell Lung Cancer

Competing Products

1 competing product in Locally-Advanced Non-Small Cell Lung Cancer

See all competitors

Product	Company	Stage	Hype Score
BYL719 + Letrozole + Exemestane	Novartis	Phase 1	33

Other Products from Nanobiotix

NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRTPhase 1/2

NBTXR3 + Nivolumab + PembrolizumabPhase 1